BioSpace News Archive

Business

Triventures, Leading Healthcare Investor, Backs Genoox in $6 Million Funding Round

Genoox, today announced it closed a $6 million funding round.

May 15, 2018

·

4 min read

Business

Biogennix Reports Additional 33% Growth in Q1

Biogennix announced today that it saw 33% growth for the first quarter of 2018.

May 15, 2018

·

1 min read

Deals

Verastem Oncology Announces Public Offering of Common Stock

Verastem, Inc. (NASDAQ: VSTM) today announced that it has commenced a registered underwritten public offering of $35 million of its shares of common stock.

May 15, 2018

·

4 min read

Aurobindo Pharma Launches Oral Contraceptives

Aurobindo Pharma Limited has launched Mili™ and Tri-Mili™ lines of oral contraceptive tablets.

May 15, 2018

·

1 min read

Policy

TapImmune and Marker Therapeutics Announce Entry into Merger Agreement, Creating a Transformational Immuno-Oncology Platform

TapImmune Inc. (NASDAQ: TPIV) (“TapImmune”) today announced that it has entered into a definitive merger agreement to acquire Marker Therapeutics, Inc. (“Marker”), a privately-held clinical-stage developer of a transformative, non-genetically engineered, multi-antigen T cell therapy platform.

May 15, 2018

·

16 min read

Biotech Bay

FDA Clears Expanded Claims for ‘Superbug’ Test

Xpert® Carba-R now FDA-cleared to aid clinicians in determining appropriate therapeutic strategy for pure colony specimens

May 15, 2018

·

2 min read

Drug Development

Intec Pharma Reports First Quarter 2018 Financial Results and Corporate Update

Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: NTEC) (“Intec” or “the Company”) today announces financial results for the three months ended March 31, 2018 and provides a corporate update.

May 15, 2018

·

8 min read

Job Trends

Agilvax Closes A1 Financing to Expand Pre-IND Studies for AX09 In Triple Negative Breast Cancer

The funds will be used to expand the pre-IND studies for its lead program AX09 in triple negative breast cancer (TNBC).

May 15, 2018

·

2 min read

Biotech Bay

Grant Opportunity Invites Collaborations to Advance Inflammatory Bowel Disease Research

Proposals for Synergy Awards will be accepted online through September 17, 2018.

May 15, 2018

·

2 min read

Drug Development

Lilly’s Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache

A statistically significantly greater percentage of patients treated with galcanezumab also achieved at least a 50 percent reduction in weekly cluster headache attacks compared to placebo at Week 3

May 15, 2018

·

8 min read